Grail
GRAIL Inc is an American healthcare and biotechnology company developing blood tests for early cancer detection. The company utilizes high-intensity methylation sequencing, machine learning algorithms, and circulating tumor DNA science to identify multiple cancer types from single blood samples. Main revenue drivers include commercial sales of the Galleri multi-cancer early detection blood test and biopharmaceutical clinical research partnerships. GRAIL serves healthcare systems, self-insured employers, medical practitioners, and biopharmaceutical development partners across the United States and international markets. The company holds a pioneer position in multi-cancer early detection testing technology using liquid biopsy platforms. Headquartered in Menlo Park, California, GRAIL Inc is listed on the Nasdaq Stock Market.
7 of the funds FundTelligence covers report a position in Grail.
- Legal name
- GRAIL Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
- Exposure themes
- Molecular Diagnostics, Multi-Cancer Early Detection, Precision Medicine & Genomics
Funds holding Grail
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.54 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.48 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.35 % (full portfolio disclosed, October 2026)
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.32 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.08 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.06 % (full portfolio disclosed, September 2026)
- Nordea Internationale aktier — Nordea Funds · 0.02 % (full portfolio disclosed, September 2026)